Please assess the completion status of the following clinical trial:

Trial Title: Testosterone & Tamoxifen Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. A history of proven ER+ (\>10% of cells), AR+ (\>10% of cells), and HER2- metastatic BC~3. Tumor progression after at least one line of conventional endocrine therapy (tamoxifen, AI, fulvestrant, CDK4/6, ±LHRH analogue).~4. Age ≥ 18 years~5. Adequate hematological, renal and liver function as follows:~   * Absolute neutrophil count \> 1.5 x 109/L~  * Platelet count \>100 x 109/L~  * White blood cell count \>3 x 109/L~  * AST and ALT \<2.5 or \<5.0 in case of liver metastases x upper limit of normal (ULN)~  * Creatinine clearance \>50mL/min~  * Prothrombin time, partial thromboplastin time and INR \<1.5 x ULN~6. Written informed consent~Exclusion Criteria:~1. History of prostate, testicular or liver cancer~2. Patients already using testosterone supplements~3. Patients using medication with anti-androgenic effects (e.g. spironolactone)~4. Elevated PSA (\>4μg/L) or severe urinary tract problems (as defined with a Prostate Symptom Score \>19). Patients with known BRCA mutation and PSA \>3 μg/L will be referred to the urologist for prostate cancer screening, and can participate if they have no signs of prostate cancer.~5. Hematocrit \>50%~6. Patients with uncontrolled hypertension, diabetes mellitus or other significant cardiovascular morbidity.~7. Patients with recent history of coronary artery disease or trombo-embolic events within 6 months prior to screening~8. Severe concurrent disease, infection, co morbid condition that, in the judgment of the investigator would make the patient inappropriate for enrollment~9. Visceral crisis and/or rapid progression necessitating chemotherapy~10. Previous allergic reaction to androgen agonists~11. Contra-indication for PET imaging~12. Tamoxifen or fulvestrant treatment \<5 weeks prior to FES-PET.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).